DK3692983T3 - Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf - Google Patents

Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK3692983T3
DK3692983T3 DK19213148.0T DK19213148T DK3692983T3 DK 3692983 T3 DK3692983 T3 DK 3692983T3 DK 19213148 T DK19213148 T DK 19213148T DK 3692983 T3 DK3692983 T3 DK 3692983T3
Authority
DK
Denmark
Prior art keywords
procedures
oral formulations
cytidine analogs
cytidine
analogs
Prior art date
Application number
DK19213148.0T
Other languages
English (en)
Inventor
Jeffrey B Etter
Mei Lai
Jay T Backstrom
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40941609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3692983(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of DK3692983T3 publication Critical patent/DK3692983T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK19213148.0T 2008-05-15 2009-05-14 Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf DK3692983T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5360908P 2008-05-15 2008-05-15
US20114508P 2008-12-05 2008-12-05
US15787509P 2009-03-05 2009-03-05
EP13182721.4A EP2695609B1 (en) 2008-05-15 2009-05-14 Oral formulations of cytidine analogs and methods of use thereof

Publications (1)

Publication Number Publication Date
DK3692983T3 true DK3692983T3 (da) 2021-09-20

Family

ID=40941609

Family Applications (5)

Application Number Title Priority Date Filing Date
DK20201105.2T DK3782611T3 (da) 2008-05-15 2009-05-14 Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
DK19213148.0T DK3692983T3 (da) 2008-05-15 2009-05-14 Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
DK13182721.4T DK2695609T3 (da) 2008-05-15 2009-05-14 Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
DK20201143.3T DK3782612T3 (da) 2008-05-15 2009-05-14 Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
DK09746975.3T DK2299984T3 (da) 2008-05-15 2009-05-14 Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK20201105.2T DK3782611T3 (da) 2008-05-15 2009-05-14 Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK13182721.4T DK2695609T3 (da) 2008-05-15 2009-05-14 Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
DK20201143.3T DK3782612T3 (da) 2008-05-15 2009-05-14 Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
DK09746975.3T DK2299984T3 (da) 2008-05-15 2009-05-14 Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf

Country Status (34)

Country Link
US (11) US8846628B2 (da)
EP (6) EP2695609B1 (da)
JP (3) JP2011520880A (da)
KR (1) KR101633134B1 (da)
CN (3) CN103479586B (da)
AR (1) AR071808A1 (da)
AU (3) AU2009246926B2 (da)
BR (1) BRPI0912717A2 (da)
CA (3) CA2761582C (da)
CL (2) CL2009001170A1 (da)
CO (1) CO6300930A2 (da)
CR (1) CR11789A (da)
CY (3) CY1121350T1 (da)
DK (5) DK3782611T3 (da)
EC (1) ECSP10010665A (da)
ES (5) ES2893785T3 (da)
FI (1) FI3782612T3 (da)
HR (5) HRP20221064T1 (da)
HU (5) HUE064677T2 (da)
IL (2) IL238087B (da)
LT (5) LT2299984T (da)
MX (2) MX2010012470A (da)
MY (1) MY161593A (da)
NI (1) NI201000193A (da)
NZ (3) NZ602833A (da)
PE (2) PE20091971A1 (da)
PL (5) PL3692983T3 (da)
PT (5) PT2695609T (da)
RU (3) RU2476207C2 (da)
SG (1) SG193206A1 (da)
SI (5) SI2695609T1 (da)
TW (3) TW201513869A (da)
WO (1) WO2009139888A1 (da)
ZA (1) ZA201008229B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
JP2011505336A (ja) * 2007-11-01 2011-02-24 セルジーン コーポレイション 骨髄異形成症候群治療のためのシチジンアナログ
CN103479586B (zh) * 2008-05-15 2017-03-01 细胞基因公司 胞苷类似物的口服制剂和其使用方法
US20150290228A1 (en) * 2008-05-15 2015-10-15 Jay T. BACKSTROM Oral formulations of cytidine analogs and methods of use thereof
US8492361B2 (en) 2009-02-10 2013-07-23 Celgene Corporation Methods for treating non-small cell lung cancer using 5-azacytidine
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
CA2801891C (en) * 2010-06-07 2020-10-27 Abraxis Bioscience, Llc Combination therapy methods for treating proliferative diseases
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
US20110301102A1 (en) * 2010-06-07 2011-12-08 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
WO2012106299A1 (en) * 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
EP2481813A1 (en) * 2011-02-01 2012-08-01 Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano Markers of cutaneous melanoma and uses thereof
WO2012135405A1 (en) 2011-03-31 2012-10-04 Pharmion Llc Systhesis of 5-azacytidine
AU2012318239B2 (en) * 2011-11-01 2015-07-09 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
EP2773360B1 (en) 2011-11-03 2018-02-28 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
MX2015000804A (es) * 2012-07-20 2016-03-11 Star Biotechnology Llc Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1.
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CN112159391A (zh) 2014-03-14 2021-01-01 阿吉奥斯制药公司 治疗活性化合物的药物组合物
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
HUE061382T2 (hu) 2014-08-22 2023-06-28 Celgene Corp Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
JP2018515566A (ja) * 2015-05-22 2018-06-14 ノバルティス アーゲー 医薬組成物
IL258684B2 (en) 2015-10-15 2023-04-01 Agios Pharmaceuticals Inc Combination therapy including an isocitrate dehydrogenase (1idh) inhibitor for use in the treatment of acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of 1idh
MX2018004586A (es) * 2015-10-15 2018-08-16 Agios Pharmaceuticals Inc Terapia de combinacion para tratar tumores malignos.
SG10201912869WA (en) * 2015-10-15 2020-02-27 Celgene Corp Combination therapy for treating malignancies
EP3383406B1 (en) 2015-12-03 2021-10-20 Epidestiny, Inc. Compositions containing decitabine, 5-azacytidine and tetrahydrouridine and uses thereof
US11035850B2 (en) 2016-04-12 2021-06-15 The Johns Hopkins University Quantitative determination of nucleoside analogue drugs in genomic DNA or RNA
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
EA039874B1 (ru) * 2019-06-06 2022-03-22 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
BR112021025375A2 (pt) 2019-06-20 2022-02-01 Celgene Corp Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para tratamento de leucemia ou síndrome mielodisplástica
KR20220103947A (ko) 2019-10-21 2022-07-25 노파르티스 아게 베네토클락스 및 tim-3 억제제를 사용한 조합 요법
TW202128191A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 Tim-3抑制劑及其用途
CA3165274A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
JP2023510393A (ja) 2020-01-17 2023-03-13 ノバルティス アーゲー 骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ
WO2022020747A1 (en) 2020-07-23 2022-01-27 Southern Research Institute Polymorophs of 5-aza-4'-thio-2-deoxycytidine
WO2022133323A1 (en) * 2020-12-18 2022-06-23 Southern Research Institute 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections
US20240229156A1 (en) 2021-03-12 2024-07-11 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
EP4419075A1 (en) 2021-10-19 2024-08-28 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913408A (en) 1956-12-28 1959-11-17 Dow Chemical Co Corrosion inhibitors for ferrous metals in aqueous solutions of non-oxidizing acids
GB1050899A (da) 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
JPS59151784U (ja) 1983-03-30 1984-10-11 日産自動車株式会社 トラツクのリヤボデイ構造
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DE59009525D1 (de) 1989-05-10 1995-09-21 Hoffmann La Roche Herstellung von Isochinolinderivaten.
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5700640A (en) 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en) 1994-10-17 1996-07-23 Trojan Technologies Inc. Method of cleaning fouling materials from a radiation module
PT1027359E (pt) 1996-10-16 2003-09-30 Ribapharm Inc L-nucleosideos monociclicos analogos e suas utilizacoes
JP4083818B2 (ja) 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US6803195B1 (en) 1999-07-02 2004-10-12 Ramot At Tel-Aviv University Ltd. Facile detection of cancer and cancer risk based on level of coordination between alleles
WO2001005406A1 (fr) 1999-07-16 2001-01-25 Amato Pharmaceutical Products, Ltd. Preparations de glycyrrhizine pour absorption par voie transmuqueuse
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
EP1399159A4 (en) 2001-06-01 2007-02-14 Cytovia Inc 4-SUBSTITUTE-1- (ARYLMETHYLIDENE) THIOSEMICARBAZIDE, 4-SUBSTITUTE-1- (ARYLCARBONYL) THIOSEMICARBAZIDE AND ANALOGUES AS ACTIVATORS OF APOPTOSIS CAPSASES AND TRIGS, AND USE THEREOF
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030220254A1 (en) 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
AU2003278904A1 (en) 2002-09-24 2004-04-19 Kornis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
AU2003286836A1 (en) 2002-10-31 2004-06-07 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
WO2004058253A1 (en) 2002-12-18 2004-07-15 Cytovia, Inc. 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
EP1628651A2 (en) 2003-05-21 2006-03-01 Novartis AG Combination of histone deacetylase inhibitors with chemotherapeutic agents
AU2004270150C1 (en) * 2003-08-29 2011-07-14 Merck Hdac Research, Llc Combination methods of treating cancer
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
CN100374160C (zh) * 2004-11-22 2008-03-12 山东蓝金生物工程有限公司 一种含抗代谢类药物的抗癌药物组合物
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
PT2301531T (pt) 2005-02-18 2018-07-30 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
ATE482693T1 (de) 2005-03-07 2010-10-15 Bayer Schering Pharma Ag Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
CN100500212C (zh) * 2005-04-06 2009-06-17 山东蓝金生物工程有限公司 一种抗实体肿瘤药物组合物
US8058260B2 (en) 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
US20080057086A1 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
WO2008088779A2 (en) 2007-01-11 2008-07-24 Ivax Pharmaceuticals S.R.O. Solid state forms of 5-azacytidine and processes for preparation thereof
WO2008092127A1 (en) 2007-01-25 2008-07-31 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
JP5173298B2 (ja) 2007-07-25 2013-04-03 キヤノン株式会社 プリント配線板およびそれを用いた電子機器
EP2176279A4 (en) 2007-08-02 2012-01-11 Chemagis Ltd HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
BRPI0817269A2 (pt) 2007-09-26 2014-10-07 Sinai School Medicine Análogos de azacitidina e usos dos mesmos
EP2048151A1 (en) 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
JP2011505336A (ja) 2007-11-01 2011-02-24 セルジーン コーポレイション 骨髄異形成症候群治療のためのシチジンアナログ
CN103479586B (zh) * 2008-05-15 2017-03-01 细胞基因公司 胞苷类似物的口服制剂和其使用方法
WO2010014883A2 (en) 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
WO2010017374A1 (en) 2008-08-06 2010-02-11 Sicor Inc. Process for preparing azacytidine intermediate
JP5650643B2 (ja) 2008-08-08 2015-01-07 サイノファーム タイワン リミテッド ５−アザシトシンヌクレオシド及びその誘導体の製造方法
MX340724B (es) 2008-11-22 2016-07-22 Genentech Inc Terapia anti-angiogenesis para el tratamiento del cancer de mama.
US20110042247A1 (en) 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina
WO2012106299A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
WO2012135405A1 (en) 2011-03-31 2012-10-04 Pharmion Llc Systhesis of 5-azacytidine
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
AU2012318239B2 (en) 2011-11-01 2015-07-09 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs

Also Published As

Publication number Publication date
US12053482B2 (en) 2024-08-06
AU2015202884A1 (en) 2015-06-18
PT3692983T (pt) 2021-11-08
PL2299984T3 (pl) 2019-07-31
LT2695609T (lt) 2020-02-10
NZ589437A (en) 2012-11-30
HRP20190100T1 (hr) 2019-04-05
ES2774226T3 (es) 2020-07-17
US20180153916A1 (en) 2018-06-07
JP2017137326A (ja) 2017-08-10
HRP20200096T1 (hr) 2020-04-03
DK3782612T3 (da) 2024-01-15
US11571436B2 (en) 2023-02-07
US10463683B2 (en) 2019-11-05
SI3692983T1 (sl) 2021-11-30
EP3692983A1 (en) 2020-08-12
JP6426778B2 (ja) 2018-11-21
WO2009139888A1 (en) 2009-11-19
US20190231803A1 (en) 2019-08-01
AU2009246926B2 (en) 2014-06-26
DK2695609T3 (da) 2020-02-10
CL2013001097A1 (es) 2013-11-29
CY1121350T1 (el) 2020-05-29
ES2712506T3 (es) 2019-05-13
KR20110015629A (ko) 2011-02-16
LT3782612T (lt) 2023-12-27
TWI522103B (zh) 2016-02-21
NZ602833A (en) 2014-04-30
AU2015202884B2 (en) 2017-02-23
PL3782612T3 (pl) 2024-03-04
SG193206A1 (en) 2013-09-30
PT2299984T (pt) 2019-02-25
US20090286752A1 (en) 2009-11-19
CR11789A (es) 2011-02-21
LT3782611T (lt) 2022-10-10
PE20142440A1 (es) 2015-01-28
SI2695609T1 (sl) 2020-03-31
IL209307A (en) 2016-02-29
EP4327888A2 (en) 2024-02-28
RU2012147739A (ru) 2014-05-20
DK3782611T3 (da) 2022-09-05
SI3782611T1 (sl) 2022-10-28
SI3782612T1 (sl) 2024-02-29
NI201000193A (es) 2011-08-01
CN103479586A (zh) 2014-01-01
US20220079964A1 (en) 2022-03-17
SI2299984T1 (sl) 2019-04-30
NZ623495A (en) 2015-08-28
CL2009001170A1 (es) 2010-06-04
JP2015110575A (ja) 2015-06-18
EP3782611B1 (en) 2022-07-06
EP3692983B1 (en) 2021-08-11
HUE055911T2 (hu) 2021-12-28
US20150374732A1 (en) 2015-12-31
EP2695609B1 (en) 2019-12-11
MX363023B (es) 2019-03-05
HRP20211398T1 (hr) 2021-12-10
TW201729817A (zh) 2017-09-01
US10646503B2 (en) 2020-05-12
IL209307A0 (en) 2011-01-31
CN105535008A (zh) 2016-05-04
HRP20221064T1 (hr) 2022-11-11
EP2695609A1 (en) 2014-02-12
PT3782612T (pt) 2024-01-18
TWI618538B (zh) 2018-03-21
TW201513869A (zh) 2015-04-16
LT3692983T (lt) 2021-11-10
US20220105118A1 (en) 2022-04-07
US20200316099A1 (en) 2020-10-08
ES2893785T3 (es) 2022-02-10
PT3782611T (pt) 2022-11-18
EP3782612B1 (en) 2023-11-08
US20150056280A1 (en) 2015-02-26
IL238087B (en) 2019-01-31
DK2299984T3 (da) 2019-03-04
CA3094590A1 (en) 2009-11-19
HUE064677T2 (hu) 2024-04-28
AU2009246926A1 (en) 2009-11-19
FI3782612T3 (fi) 2024-01-16
EP3782611A1 (en) 2021-02-24
ECSP10010665A (es) 2011-01-31
HUE059635T2 (hu) 2022-12-28
ES2969144T3 (es) 2024-05-16
HRP20231439T1 (hr) 2024-03-01
ZA201008229B (en) 2012-02-29
JP2011520880A (ja) 2011-07-21
AU2013202665B2 (en) 2015-06-25
PT2695609T (pt) 2020-03-02
RU2476207C2 (ru) 2013-02-27
US20200101095A1 (en) 2020-04-02
EP2299984B1 (en) 2018-11-28
MX2010012470A (es) 2010-12-02
CA3094580C (en) 2021-05-18
RU2018109222A3 (da) 2021-07-02
CA2761582A1 (en) 2009-11-19
PL3692983T3 (pl) 2021-12-27
HUE047707T2 (hu) 2020-05-28
CN102099018B (zh) 2016-01-13
ES2927556T3 (es) 2022-11-08
US20230255996A1 (en) 2023-08-17
AU2013202665A1 (en) 2013-05-02
CN103479586B (zh) 2017-03-01
TW201006478A (en) 2010-02-16
EP2299984A1 (en) 2011-03-30
RU2018109222A (ru) 2019-09-17
LT2299984T (lt) 2019-03-25
CA2761582C (en) 2022-06-07
CA3094580A1 (en) 2009-11-19
JP6105547B2 (ja) 2017-03-29
CY1122681T1 (el) 2020-10-14
HUE042825T2 (hu) 2019-07-29
EP4327888A3 (en) 2024-05-22
CO6300930A2 (es) 2011-07-21
US20230241086A1 (en) 2023-08-03
CY1124720T1 (el) 2022-07-22
US10220050B2 (en) 2019-03-05
US8846628B2 (en) 2014-09-30
AR071808A1 (es) 2010-07-14
BRPI0912717A2 (pt) 2014-12-23
RU2765076C2 (ru) 2022-01-25
KR101633134B1 (ko) 2016-06-23
MY161593A (en) 2017-04-28
RU2010151428A (ru) 2012-06-20
PE20091971A1 (es) 2010-01-15
CN102099018A (zh) 2011-06-15
PL2695609T3 (pl) 2020-05-18
EP3782612A1 (en) 2021-02-24
PL3782611T3 (pl) 2022-11-07

Similar Documents

Publication Publication Date Title
DK3692983T3 (da) Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
DK3045043T3 (da) Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK2334378T3 (da) Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
DK3092901T3 (da) Quinolonanaloger og fremgangsmåder relateret dertil
DK2152078T3 (da) Formuleringer indeholdende clopidogrel og sulfoalkylethercyclodextrin og anvendelsesfremgangsmåder
DK2480559T3 (da) Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
DK2084174T3 (da) Fremstilling af ribofuranosylpyrimidinnukleotider
DK3461503T3 (da) Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder
DK3011975T3 (da) Faststofsammensætning til oral administration af farvestoffer og diagnostisk anvendelse deraf
DK3300743T3 (da) Fremgangsmåder til indgivelse af vaccine
DK2557924T3 (da) Dermale farmaceutiske sammensætninger af 1-methyl-2',6'-pipecoloxylidid og fremgangsmåde til deres anvendelse
DK2367542T3 (da) Orale doseringsformer af bendamustin
DK2097068T3 (da) Formuleringer af peg-interferon-alpha-konjugater
DK3348258T3 (da) Orale og injicerbare formuleringer af tetracyclinforbindelser
DK3494960T3 (da) Stabiliserede sammensætninger af alkyleringsmidler og fremgangsmåder til anvendelse af samme
DK2219611T3 (da) Farmaceutiske formuleringer til frigivelse af aktive forbindelser
DK2275098T3 (da) Hidtil ukendte orale formulationer af ospemifen
IS8612A (is) Stöðugar statínlyfjasamsetningar